# LANTIDRA

NDC: 73539-001
Generic name: DONISLECEL
Labeler / Manufacturer: CellTrans Inc.
Product type: CELLULAR THERAPY
Marketing category: Biologic License Application
Dosage form: SOLUTION
Routes: INTRAVASCULAR
Marketing started: 20230628

FDA application: BLA125734

## Active ingredients

- DONISLECEL: 5000 [arb'U]/400mL

## Pharmacological class

—

## External sources

- openFDA: https://api.fda.gov/drug/ndc.json?search=product_ndc:"73539-001"
- FDA NDC Directory: https://www.accessdata.fda.gov/scripts/cder/ndc/dsp_searchresult.cfm?p_ndc=73539-001
- DailyMed: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=24610d9f-0c5a-4f55-93b3-d456300bfd5d